読み込み中
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
終値時点
$0.375
−$0.004 · -1.06%
時間外
$0.38
+$0.005 · +1.33%
10月9日 19:09 ET
日中の時刻はETです。市場データは遅延する場合があります。
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
日中レンジ
現在 $0.375
52週レンジ
現在 $0.375
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
82
大幅な割安
センチメント
58
まちまち
リスク
79
高リスク
モメンタム
17
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
日中レンジ
現在 $0.375
52週レンジ
現在 $0.375
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 204.51万 USD | 175.23万 USD | 142.43万 USD | 1105.91万 USD | 962.23万 USD |
| 売上原価 | 144.06万 USD | 139.2万 USD | 131.52万 USD | 593.74万 USD | 492.74万 USD |
| 粗利益 | 60.45万 USD | 36.03万 USD | 10.91万 USD | 512.17万 USD | 469.5万 USD |
| 研究開発 | 59.26万 USD | 126.18万 USD | 140.92万 USD | 12万 USD | 19.34万 USD |
| 販売・一般管理 | 334.28万 USD | 475.96万 USD | 506.15万 USD | 332.28万 USD | 255.95万 USD |
| 営業費用 | 393.54万 USD | 602.14万 USD | 647.06万 USD | 344.29万 USD | 275.29万 USD |
| 受取利息 | 2.14万 USD | 7.95万 USD | 20.92万 USD | 6.84万 USD | 2994 USD |
| 支払利息 | 15.62万 USD | 1.26万 USD | 2.79万 USD | 1.57万 USD | 1.29万 USD |
| 減価償却費と償却費 | 7.8万 USD | 13.58万 USD | 16.73万 USD | 28.87万 USD | 12.37万 USD |
| 営業利益 | −333.09万 USD | −566.11万 USD | −636.15万 USD | 167.89万 USD | 194.21万 USD |
| 純利益 | −373.88万 USD | −555.17万 USD | −639.13万 USD | 218.69万 USD | 207.18万 USD |
会社概要が更新されました 2026年10月10日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$5.00
上昇余地（1233.33%）この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
